China Pharma Holdings, Inc. has begun a clinical trial of a generic version of the hypertension drug Candesartan. China Pharma expects the trial will take 18 months to complete. Originally developed by Takeda Pharma of Japan together with AstraZeneca, Cardesartan is a front-line treatment for hypertension. It produced $2.5 billion in revenues worldwide during 2007. China Pharma is actively adding to its portfolio of generic drugs. More details...

Stock Symbols: (OTCBB: CPHI) (NYSE: AZN)